inhaled/swallowed budesonide
PreclinicalSmall molecule
inhaled/swallowed budesonide is one of 15 small molecule programs targeting Eosinophilic Esophagitis. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
14
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
18 competitors in Eosinophilic Esophagitis
#DrugCompanyPhaseTrials
1Pulmicort
SSalix
Approved
Dupixent
AAzienda U.S.L. 1 di Massa e Carrara
Approved
Flovent
PParatek Pharmaceuticals Inc
Approved
Prevacid
TakedaApproved
Flovent
PParatek Pharmaceuticals Inc
Approved
Prilosec
DDexcel Pharma Technologies Ltd.
Approved
Tezspire
AstraZenecaPhase 3
CC-93538
Bristol-Myers SquibbPhase 3
Omeprazole BID
UUniversity of Colorado, Denver
Phase 3
Solrikitug
UUniquity One (UNI)
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details